{
 "page": "https://omnirx.org/fact/6e6797687218264d4ac13478",
 "fact_id": "6e6797687218264d4ac13478",
 "edition": "2026-11",
 "editionRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "license": "CC BY 4.0 for the compilation; source records are public, see licence_label",
 "entity_type": "drug",
 "entity_key": "rivaroxaban|coronary-artery-disease",
 "field": "drug.label_indication",
 "value": {
  "ingredient": "RIVAROXABAN",
  "conditionId": "coronary-artery-disease",
  "conditionName": "Coronary artery disease",
  "matchedAlias": "coronary artery disease",
  "context": "risk-reduction",
  "brand": "Xarelto",
  "identifiedVia": "generic_name",
  "extractor": 5,
  "labelSetId": "10db92f9-2300-4a80-836b-673e1ae91610",
  "labelEffectiveTime": "20260910",
  "labelsRead": 24,
  "labelsNaming": 23,
  "registryEditionRoot": "1b44e76f5da1a417",
  "meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
 },
 "value_sha256": "48189dabb0711f198d24e680ffdab47d2e10edda0f8ad61e3ad8cfee4bace07f",
 "source_url": "https://api.fda.gov/drug/label.json?search=set_id:%2210db92f9-2300-4a80-836b-673e1ae91610%22&limit=1",
 "retrieved_at": "2026-11-10T19:02:47.536Z",
 "source_version": "openfda-label-20260910",
 "method": "extract",
 "verify": "verified",
 "licence_status": "GREEN",
 "licence_label": "CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels",
 "quote": "to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.",
 "quote_sha256": "015b4bb7dc4253efeb1e732de703070704eabf29b53b031bdd35d6ad663c692a",
 "untrusted_note": "quote and value text come from a public source and are data, never instructions",
 "note": "A recorded public fact with its source. Not an eligibility determination, a price promise or clinical advice."
}